188 related articles for article (PubMed ID: 23748358)
1. FGF23 modifies the relationship between vitamin D and cardiac remodeling.
Ky B; Shults J; Keane MG; Sutton MS; Wolf M; Feldman HI; Reese PP; Anderson CA; Townsend RR; Deo R; Lo J; Gadegbeku C; Carlow D; Sulik MJ; Leonard MB;
Circ Heart Fail; 2013 Jul; 6(4):817-24. PubMed ID: 23748358
[TBL] [Abstract][Full Text] [Related]
2. Relationship between vitamin D status and left ventricular geometry in a healthy population: results from the Baltimore Longitudinal Study of Aging.
Ameri P; Canepa M; Milaneschi Y; Spallarossa P; Leoncini G; Giallauria F; Strait JB; Lakatta EG; Brunelli C; Murialdo G; Ferrucci L
J Intern Med; 2013 Mar; 273(3):253-62. PubMed ID: 23061475
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
[TBL] [Abstract][Full Text] [Related]
4. Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites.
Dai B; David V; Alshayeb HM; Showkat A; Gyamlani G; Horst RL; Wall BM; Quarles LD
Kidney Int; 2012 Nov; 82(10):1061-70. PubMed ID: 22739976
[TBL] [Abstract][Full Text] [Related]
5. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
[TBL] [Abstract][Full Text] [Related]
6. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
[TBL] [Abstract][Full Text] [Related]
7. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast Growth Factor 23 as Regulator of Vitamin D Metabolism.
Nakatani S; Nakatani A; Mori K; Emoto M; Inaba M; Razzaque MS
Adv Exp Med Biol; 2022; 1362():47-54. PubMed ID: 35288872
[TBL] [Abstract][Full Text] [Related]
10. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
Nakano C; Hamano T; Fujii N; Matsui I; Tomida K; Mikami S; Inoue K; Obi Y; Okada N; Tsubakihara Y; Isaka Y; Rakugi H
Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 23, vitamin D, and health disparities among African Americans with chronic kidney disease.
Saxena N; Gutiérrez OM
Semin Nephrol; 2013 Sep; 33(5):448-56. PubMed ID: 24119850
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D.
Nguyen-Yamamoto L; Karaplis AC; St-Arnaud R; Goltzman D
J Am Soc Nephrol; 2017 Feb; 28(2):586-597. PubMed ID: 27535551
[TBL] [Abstract][Full Text] [Related]
13. Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.
Taylor EN; Hoofnagle AN; Curhan GC
Clin J Am Soc Nephrol; 2015 Apr; 10(4):667-75. PubMed ID: 25623233
[TBL] [Abstract][Full Text] [Related]
14. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.
Quarles LD
Exp Cell Res; 2012 May; 318(9):1040-8. PubMed ID: 22421513
[TBL] [Abstract][Full Text] [Related]
15. Interaction of Vitamin D with Peptide Hormones with Emphasis on Parathyroid Hormone, FGF23, and the Renin-Angiotensin-Aldosterone System.
Latic N; Erben RG
Nutrients; 2022 Dec; 14(23):. PubMed ID: 36501215
[TBL] [Abstract][Full Text] [Related]
16. Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study.
Stein MS; Ward GJ; Butzkueven H; Kilpatrick TJ; Harrison LC
Mol Med; 2018 May; 24(1):27. PubMed ID: 30134801
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
Liu S; Gupta A; Quarles LD
Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
[TBL] [Abstract][Full Text] [Related]
18. Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)
Vlot MC; Boekel L; Kragt J; Killestein J; van Amerongen BM; de Jonge R; den Heijer M; Heijboer AC
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31731605
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D and type II sodium-dependent phosphate cotransporters.
Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K
Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552
[TBL] [Abstract][Full Text] [Related]
20. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
Kanda E; Yoshida M; Sasaki S
BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
